Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Gut microbial metabolites alter IgA immunity in type 1 diabetes
Juan Huang, … , Zhiguang Zhou, Li Wen
Juan Huang, … , Zhiguang Zhou, Li Wen
Published April 16, 2020
Citation Information: JCI Insight. 2020;5(10):e135718. https://doi.org/10.1172/jci.insight.135718.
View: Text | PDF
Research Article

Gut microbial metabolites alter IgA immunity in type 1 diabetes

  • Text
  • PDF
Abstract

The incidence of type 1 diabetes (T1D) has been increasing among children and adolescents, in which environmental factors, including gut microbiota, play an important role. However, the underlying mechanisms are yet to be determined. Here, we show that patients with newly diagnosed T1D displayed not only a distinct profile of gut microbiota associated with decreased short-chain fatty acids (SCFAs) production, but also an altered IgA-mediated immunity compared with healthy control subjects. Using germ-free NOD mice, we demonstrate that gut microbiota from patients with T1D promoted different IgA-mediated immune responses compared with healthy control gut microbiota. Treatment with the SCFA, acetate, reduced gut bacteria–induced IgA response accompanied by decreased severity of insulitis in NOD mice. We believe our study provides new insights into the functional effects of gut microbiota on inducing IgA immune response in T1D, suggesting that SCFAs might be potential therapeutic agents in T1D prevention and/or treatment.

Authors

Juan Huang, James A. Pearson, Jian Peng, Youjia Hu, Sha Sha, Yanpeng Xing, Gan Huang, Xia Li, Fang Hu, Zhiguo Xie, Yang Xiao, Shuoming Luo, Chen Chao, F. Susan Wong, Zhiguang Zhou, Li Wen

×

Figure 1

Stool SCFA production and bacteria-targeting IgA response in individuals with T1D compared with control subjects.

Options: View larger image (or click on image) Download as PowerPoint
Stool SCFA production and bacteria-targeting IgA response in individuals...
(A) Experimental design of the study in patients with T1D and healthy control subjects. (B–G) Stool microbiota composition was investigated by 16S rRNA sequencing (n = 19/group). Changes in α diversity were assessed by Chao richness (B) and number of observed species (C). Altered relative microbial abundances of Ruminococcaceae (D), Coprococcus (E), Roseburia (F), and Megamonas (G) between donors with T1D and controls are shown. (H and I) Stool acetate (H), and butyrate (I) concentrations from individuals with T1D and control subjects (n = 19/group). (J) Correlation between stool acetate level and serum fasting C-peptide concentration (n = 15). Data are presented as mean ± SEM and were analyzed by a 2-tailed Student’s t test (B–I). Data in (J) was analyzed using a 2-tailed Pearson correlation coefficient test and linear regression. SCFAs, short-chain fatty acids; T1D, type 1 diabetes.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts